EX1.AX - Exopharm Limited

ASX - ASX Delayed price. Currency in AUD

Exopharm Limited

31 Queen Street
Level 1
Melbourne, VIC 3000
61 3 9111 0026

Full-time employees50

Key executives

NameTitlePayExercisedYear born
Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.Founder, Technology Co-Founder, CEO MD & Director429.16kN/AN/A
Dr. Michael L. West Ph.D.Chief Technology Officer196.46kN/A1964
Mr. David OxleyPres of International344.4kN/AN/A
Dr. Gregor Lichtfuss M.Sc.Co-Founder & Bus. Services Mang.N/AN/AN/A
Mr. Johannes MuhlSr. VP of Fin.N/AN/AN/A
Caitlin GladmanVP of CommunicationsN/AN/AN/A
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP.Company Sec.N/AN/A1970
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Exopharm Limited, a clinical-stage biopharmaceutical company, develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company's technology includes extracellular vesicle positioning system that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; LOAD technology platform enables loading active pharmaceutical ingredients into exosomes; and ligand-based exosome affinity purification technology solves the critical bottleneck of exosome isolation and purification. Its engineered EVs medicines are applied in the areas, such as neurology, cardiology, and oncology. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine and Showa Denko Materials Co., Ltd. The company was incorporated in 2013 and is based in Melbourne, Australia.

Corporate governance

Exopharm Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.